Request Demo
Last update 16 Aug 2025
TY-0540
Last update 16 Aug 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms TY-0540, TYK 00540, TYK-00540 + [1] |
Target |
Action inhibitors |
Mechanism CDK2 inhibitors(Cyclin-dependent kinase 2 inhibitors), CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with TY-0540NCT07104643
A Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of TYK-00540 Combined With Enzalutamide in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) That Has Failed Previous Novel Endocrine Therapy
CTR20251465
一项评价CDK2/4/6抑制剂TYK-00540片在晚期实体瘤患者中安全性、耐受性、药代动力学及有效性的I/II期临床研究
[Translation] A Phase I/II clinical study evaluating the safety, tolerability, pharmacokinetics and efficacy of the CDK2/4/6 inhibitor TYK-00540 tablets in patients with advanced solid tumors
NCT06246071
A Phase Ia/Ib, Multicenter, Open-label Study of TYK-00540, Administered Orally in Adult Patients With Locally Advanced/Metastatic Solid Tumors
100 Clinical Results associated with TY-0540
Login to view more data
100 Translational Medicine associated with TY-0540
Login to view more data
100 Patents (Medical) associated with TY-0540
Login to view more data
100 Deals associated with TY-0540
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic castration-resistant prostate cancer | Phase 2 | China | 25 Jul 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 02 Jan 2024 | |
| Hormone receptor positive HER2 negative breast cancer | Phase 2 | China | 02 Jan 2024 | |
| Biliary Tract Neoplasms | Phase 1 | China | 02 Jan 2024 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 02 Jan 2024 | |
| Platinum-Resistant Epithelial Ovarian Carcinoma | Phase 1 | China | 02 Jan 2024 | |
| Metastatic Solid Tumor | IND Approval | China | 08 Feb 2025 | |
| Pancreatic Cancer | IND Approval | China | 08 Sep 2023 | |
| Breast Cancer | IND Application | United States | 03 Mar 2023 | |
| Prostatic Cancer | IND Application | United States | 03 Mar 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free